[1]梁延秀,罗显克,王大东,等.恩替卡韦联合索拉菲尼治疗对肝细胞癌TACE治疗患者疗效的影响▲[J].内科,2019,14(06):633-635+647.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2019.06.02]
 LIANG Yanxiu,LUO Xianke,WANG Dadong,et al.Effect of entecavir combined with sorafenib on efficacy of TACE in patients with hepatocellular carcinoma[J].Internal Medicine of China,2019,14(06):633-635+647.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2019.06.02]
点击复制

恩替卡韦联合索拉菲尼治疗对肝细胞癌TACE治疗患者疗效的影响▲()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
14卷
期数:
2019年06
页码:
633-635+647
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Effect of entecavir combined with sorafenib on efficacy of TACE in patients with hepatocellular carcinoma
文章编号:
1673-7768(2019)06-0633-04
作者:
梁延秀罗显克王大东马冠英黄滟添
广西医科大学附属民族医院,广西南宁市530000
Author(s):
LIANG Yanxiu LUO Xianke WANG Dadong MA Guanying HUANG Yantian
The Affiliated ethnic Hospital of Guangxi Medical University, Nanning 530000, China
关键词:
乙型肝炎相关肝细胞癌TACE术恩替卡韦索拉菲尼
Keywords:
Hepatitis B virus related hepatocellular carcinoma Transarterial chemoembolization Entecavir Sorafenib
分类号:
R 575;R 735.7
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2019.06.02
文献标志码:
A
摘要:
目的探讨恩替卡韦联合索拉菲尼对肝细胞癌经导管肝动脉化疗栓塞(TACE)治疗患者疗效的影响。方法选取2011年1月至2017年12月在我院消化内科住院治疗的肝细胞癌患者100例,随机分为观察组和对照组,每组50例。两组患者均接受TACE术治疗,对照组患者术后给予恩替卡韦治疗,观察组患者术后给予恩替卡韦及索拉菲尼治疗,比较两组的临床治疗效果。结果治疗6个月,观察组患者的治疗总有效率(88.0%)显著高于对照组(46.0%),临床疗效优于对照组,差异有统计学意义(P<0.05);两组患者的ALT、TBIL水平均显著升高,HBV-DNA、AFP水平均显著降低;观察组患者的ALT、TBIL显著高于对照组,AFP水平显著低于对照组,差异有统计学意义(P<0.05)。随访2年,观察组患者12个月、18个月的存活率(分别为66.0%和30.0%)显著高于对照组(分别为44.0%和12.0%),差异有统计学意义(P<0.05)。结论恩替卡韦联合索拉非尼治疗,可显著提高肝细胞癌经导管肝动脉化疗栓塞治疗患者的临床效果,显著降低HBV-DNA、AFP水平,提高12个月、18个月的存活率,可作为一种治疗不能手术切除患者比较有效的方法。
Abstract:
ObjectiveTo investigate the effect of entecavir combined with sorafenib on the efficacy of transcatheter chemoembolization (TACE) for treating patients with hepatocellular carcinoma. MethodsFrom January 2011 to December 2017, 100 patients with hepatocellular carcinoma hospitalized and treated in Gastroenterology Department of our hospital were selected, and were randomly divided into observation group and control group, with 50 cases in each group. Both groups were received TACE treatment, based on which the control group was administered entecavir after operation, whereas the observation group was administered entecavir and solanib after operation. The clinical efficacy was compared between the two groups. ResultsAfter 6 months of treatment, the total effective rate in the observation group was significantly higher than that in the control group (88% vs. 46.0%), and the clinical efficacy was superior to that in the control group, with the statistically significant differences (P<0.05). The levels of ALT and TBIL significantly increased, whereas the levels of HBV-DNA and AFP significantly decreased. In comparison with the control group, patients in the observation group obtained higher ALT and TBIL, while a lower AFP level, with the statistically significant differences (P<0.05). After 2 years of follow-up, the survival rates of the observation group at 12 and 18 months (66.0% and 30.0%, respectively) were significantly higher than those of the control group (44.0% and 12.0%, respectively), with the statistically significant differences (P<0.05). ConclusionEntecavir combined with sorafenib can effectively improve the clinical effect of TACE treatment in patients with hepatocellular carcinoma, which can significantly decrease the levels of HBV-DNA and AFP; meanwhile, it can increase the survival rates of 12 months and 18 months, for it provides a relatively effective method for hepatocellular carcinoma patients who cannot receive surgical resection.

备注/Memo

备注/Memo:
▲基金项目:崇左市科学研究与技术开发计划项目(15030603)
更新日期/Last Update: 2019-12-31